Johnson & Johnson Innovation Ltd. and Lead Discovery Center GmbH (LDC) will collaborate over a two-year period to identify and accelerate innovative drug candidates for the treatment and prevention of diseases with high unmet medical needs.
 
LDC and J&J’s London Innovation Centre will work to identify translational research opportunities sourced from LDC’s academic network, including institutes from the Max Planck Society, the Helmholtz Association and various universities.

J&J will review and evaluate the opportunities with the goal of establishing drug discovery collaborations with LDC. For each project selected, the partners will negotiate a collaboration agreement for its joint development at the LDC for agreed upon milestones. Any revenue received from commercialization will be shared with the academic and collaborating institutions.
 
“Through our academic network, we have access to a broad range of exciting molecular targets, pathobiological mechanisms and new therapeutic approaches which are the basis for project proposals with a high innovation potential for drug discovery,” said Dr. Bert Klebl, chief executive officer of the LDC. “Together with Johnson & Johnson Innovation, we will now be able to offer a solution for more of our academic partners to translate their innovative findings into benefit for patients. We very much look forward to leveraging our interests, expertise and capabilities together with Johnson & Johnson Innovation to incubate additional collaborative projects at the LDC.”